New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect | NVO Stock News

Author's Avatar
May 22, 2025
Article's Main Image
  • Novo Nordisk (NVO, Financial) offers a $199 first-month pricing for Wegovy® for self-paying patients, valid until June 30, 2025, followed by a $499 monthly cost.
  • The FDA has banned the mass compounding of "semaglutide," with Novo Nordisk taking legal actions against illegal compounders.
  • Over half of the Chinese suppliers of semaglutide to the US lack proper manufacturing permits, posing safety risks, according to Novo Nordisk.

Novo Nordisk (NVO) has unveiled a strategic pricing initiative, offering a one-time $199 first-month price for new self-paying patients of Wegovy®, valid through June 30, 2025. After this introductory phase, these patients will incur a monthly cost of $499. This move aligns with the expiration of the FDA's grace period, making mass compounding of "semaglutide" illegal under US law.

The company has launched the "Choose the Real Thing" campaign to educate patients on the risks associated with unapproved versions and compounded knockoffs. Novo Nordisk is reinforcing its position by filing nearly 120 lawsuits across 34 states against illegal compounders of semaglutide, emphasizing patient safety concerns.

Analysis reveals that more than half of the Chinese suppliers exporting semaglutide to the US lack manufacturing permits in China. Novo Nordisk is committed to highlighting the dangers of these illicit drugs, urging stricter regulatory actions as unauthorized semaglutide poses significant health risks to patients. Patients interested in accessing the new Wegovy® offer can activate it through Wegovy.com or through telehealth providers.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.